US Patent

US11752106 — Pharmaceutical composition and administrations thereof

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2033-02-27 · 7y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing a solid dispersion of the active ingredient in Kalydeco, used to treat cystic fibrosis.

USPTO Abstract

The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3697 — Kalydeco
U-3697 — Kalydeco
U-3697 — Kalydeco
U-3697 — Kalydeco
U-3696 —
U-3696 —
U-3697 — Kalydeco

Patent Metadata

Patent number
US11752106
Jurisdiction
US
Classification
Method of Use
Expires
2033-02-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.